Brief: Positive Herizon-GEA-01 Phase 3 Results Support Ziihera As Her2-Targeted Agent-Of-Choice And Ziihera Combination Regimens As New Standard Of Care In First-Line Her2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
17/11/2025 11:04
Nov 17 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O: POSITIVE HERIZON-GEA-01 PHASE 3 RESULTS SUPPORT ZIIHERA® (ZANIDATAMAB-HRII) AS HER2-TARGETED AGENT-OF-CHOICE AND ZIIHERA COMBINATION REGIMENS AS NEW STANDARD OF CARE IN FIRST-LINE HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA JAZZ PHARMACEUTICALS PLC: PLANS TO SUBMIT A SUPPLEMENTAL BLA FOR THIS INDICATION IN FIRST HALF OF 2026 Source text: nPn7Z9Jnca Further company coverage: JAZZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032